🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined with Osimertinib in Patients with Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).

    The George Institute

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

  2. Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breast and colorectal cancers.

    Novartis Pharmaceuticals

    Locally advanced or metastatic unresectable colorectal cancer (CRC), Locally advanced unresectable or metastatic breast cancer (BC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC)

    phase 1 other active

    1 trial

  3. Phase I single-blind clinical trial to evaluate the safety and local immune activation of a toll-like receptor 5 agonist (FLAMOD) administered by aerosol

    The George Institute

    Pneumonia

    phase 1 other active

    1 trial

  4. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  5. Phase I-Ib clinical trial of safety and immunobiology of prophylactic infusion of lymphocytes and NK cells after Allo-HCT.

    The George Institute

    graft-versus-host disease

    phase 1 other active

    1 trial

  6. Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)

    Lacuna Pharma Pty Ltd

    Pulmonary arterial hypertension

    phase 1 other active

    1 trial

  7. Physical Activity Educational Materials

    United Therapeutics Europe Ltd

    Physical Inactivity

    phase 1 other completed

    1 trial

  8. Placebo

    Pfizer

    Respiratory Syncytial Virus Infections

    phase 1 small molecule terminated

    1 trial

  9. Placebo

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Addiction

    phase 1 small molecule completed

    1 trial

  10. Pluvicto 1 000 MBq/mL solution for injection/infusion, Lutetium (177Lu) rhPSMA-10.1 injection

    Blue Earth Diagnostics Ireland Ltd

    PSMA-positive non-curative metastatic castration-resistant prostate cancer

    phase 1 small molecule active

    1 trial

  11. Pneumococcal Vaccine, Polyvalent (23-valent)

    Praxis Precision Medicines

    HIV Infections

    phase 1 mab completed

    1 trial

  12. Pramipexole

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Addiction

    phase 1 small molecule completed

    1 trial

  13. Prednisolone

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 small molecule completed

    1 trial

  14. Prednisone

    Vertex Pharmaceuticals (Australia) Pty.

    Drug Interactions

    phase 1 small molecule completed

    1 trial

  15. Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small Cell Lung Cancer (SCLC) at diagnosis and disease progression (PASSIFLORE)

    CERO THERAPEUTICS HOLDINGS, INC.

    cell lung carcinoma

    phase 1 other active

    1 trial

  16. QL2108 injection

    Qilu Pharmaceutical (Hainan) Co.,

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial

  17. R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7

    PDS Biotechnology Corp

    High-risk HPV Infection and Biopsy-proven CIN1

    phase 1 mab completed

    1 trial

  18. REGN668: Injection Rate 1

    Regeneron UK Limited

    Healthy

    phase 1 small molecule completed

    1 trial

  19. RESTART; Autologous Transplantation of Adult Salivary Gland Stem Cells to Restore Submandibular Gland Function after Radiotherapy

    Disc Medicine

    Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.

    phase 1 other active

    1 trial

  20. Recombinant NV-A01 adenovirus injection

    The First People's Hospital of Lianyungang

    Advanced Glioblastoma Patients

    phase 1 small molecule active

    1 trial

  21. SA55 Injection

    Sinovac Research and Development Co.,

    COVID-19

    phase 1 small molecule active

    1 trial

  22. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV Infection

    phase 1 gene therapy completed

    1 trial

  23. SER-262

    Seres Therapeutics

    Clostridium Difficile Infection

    phase 1 small molecule completed

    1 trial

  24. SHP465 12.5mg

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources